Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years?

Yahoo FinanceApr 10 05:07 ET

The weight loss drug market is "too competitive", and Goldman Sachs gives Viking Therapeutics (VKTX.US) a "neutral" rating.

On Tuesday, Goldman Sachs began coverage of Viking Therapeutics (VKTX.US) with a "neutral" rating, setting a Target Price of $30 per share.

Zhitong FinanceApr 9 02:53 ET

Goldman Sachs Maintains Viking Therapeutics(VKTX.US) With Hold Rating, Maintains Target Price $30

Moomoo NewsApr 9 02:31 ET · Ratings

Viking Therapeutics Initiated at Neutral by Goldman Sachs

Dow JonesApr 8 12:09 ET · Ratings

Viking Therapeutics Draws Neutral Rating at Goldman Sachs on Competitive Headwinds

Seeking AlphaApr 8 11:26 ET

Goldman Sachs Initiates Viking Therapeutics(VKTX.US) With Hold Rating, Announces Target Price $30

Moomoo NewsApr 8 03:32 ET · Ratings